Theriva Biologics (TOVX) AI Stock Analysis

• Market Cap: $3.90M
• Dividend Yield: N/A
• Average Volume (3M): 20.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.20
• Revenue Growth: N/A
• EPS Growth: 6.87%
• Country: US
• Employees: 20
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -26.66
• Shares Outstanding: 2,782,449
• 10 Day Avg. Volume: 16,419
• 30 Day Avg. Volume: 20,896
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -3.36
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $6.00
• Price Target Upside: 334.78% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Theriva Biologics faces substantial financial difficulties with no revenue and growing losses, which is a major concern. While technical indicators show some short-term positive momentum, the long-term trend remains negative. The lack of profitability impacts valuation. However, the recent positive clinical trial results provide a potential future catalyst that could improve the company's prospects.

Positive Factors

Clinical Results

VCN-01 is being evaluated for the treatment of advanced retinoblastoma, showing promising results in reducing the number and size of vitreous seeds and resulting in complete tumor regression in some patients.

Clinical Trials

The ongoing P2b VIRAGE study in pancreatic cancer evaluating VCN-01 + gemcitabine/nab-paclitaxel has completed enrollment and is expected to report top-line data, which could represent a key catalyst for Theriva.

Investment Interest

The oncolytic virus space has been gaining traction with investors and is poised for an active period, with Theriva's VCN-01 approach being differentiated and having orphan drug and fast track designations for pancreatic cancer.

Negative Factors

Commercialization Timeline

The commercialization timelines for VCN-01 have been extended to 2030, which has contributed to lowering the price target.

Financing

The next capital raise for Theriva Biologics could be significantly dilutive given the challenging financing environment for biotech companies.

Theriva Biologics Business Overview & Revenue Model

Company Description

Theriva Biologics (TOVX) is a biotechnology company focused on the development and commercialization of therapeutics for cancer and other diseases. The company's core products involve the use of oncolytic viruses and live microbial therapeutics to enhance the efficacy of existing treatments and improve patient outcomes. By leveraging innovative biologic technologies, Theriva Biologics aims to address unmet medical needs and offer new solutions in oncology and other therapeutic areas.

How the Company Makes Money

Theriva Biologics makes money through the development, licensing, and commercialization of its proprietary biologic products. The company's revenue streams include partnerships with pharmaceutical companies for co-development and licensing agreements, which provide upfront payments, milestone payments, and royalties on sales of approved products. Additionally, the company may receive funding from grants and collaborations with research institutions that support its innovative therapeutic programs. These strategic partnerships and collaborations are significant contributors to the company's earnings, as they help to advance its product pipeline while sharing the risks and costs associated with drug development.

Theriva Biologics Financial Statement Overview

Summary

Theriva Biologics displays significant financial challenges with no revenue generation and increasing net losses. The balance sheet shows decreasing equity and assets, raising concerns about long-term viability. Negative cash flows emphasize the need for external financing to sustain operations, indicating potential liquidity risks.

Income Statement

Theriva Biologics has consistently reported zero revenue over the years, reflecting challenges in generating sales. The company has an increasing net loss trend, with the most recent figure of -$25.65 million, indicating deteriorating profitability. EBIT and EBITDA margins are deeply negative, reinforcing operational inefficiencies.

Balance Sheet

The company's debt-to-equity ratio is low, suggesting minimal leverage, a positive sign of financial stability. However, the declining stockholders' equity from $65.41 million in 2021 to $19.07 million in 2024 highlights significant financial strain. Total assets have decreased, further indicating a weakening financial position.

Cash Flow

Theriva Biologics exhibits a negative operating cash flow, with a deteriorating trend from -$12.89 million in 2021 to -$16.94 million in 2024. The free cash flow remains negative, indicating a persistent inability to generate cash from operations. Financing cash flows are positive, suggesting reliance on external funding.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-135.00K	-268.00K	-87.00K	-201.00K
	EBIT
-26.35M	-21.43M	-21.58M	-14.27M	-10.16M
	EBITDA
-26.35M	-19.85M	-21.58M	-14.19M	-9.96M
	Net Income Common Stockholders
-25.65M	-18.35M	-19.68M	-14.17M	-10.00M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
11.61M	23.18M	41.79M	67.33M	6.23M
	Total Assets
35.35M	55.22M	71.86M	70.36M	8.41M
	Total Debt
1.47M	2.15M	1.68M	1.53M	473.00K
	Net Debt
-10.14M	-21.02M	-40.10M	-65.80M	-5.75M
	Total Liabilities
16.29M	15.52M	17.30M	4.96M	3.15M
	Stockholders Equity
19.07M	39.70M	54.56M	65.41M	8.03M
Cash Flow		Free Cash Flow
-16.94M	-19.20M	-19.20M	-12.90M	-12.18M
	Operating Cash Flow
-16.94M	-19.00M	-19.08M	-12.89M	-12.17M
	Investing Cash Flow
-1.00K	-202.00K	-4.40M	-14.00K	-9.00K
	Financing Cash Flow
5.50M	625.00K	-1.93M	74.00M	3.36M

Theriva Biologics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.38
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TOVX, the sentiment is Negative. The current price of 1.38 is above the 20-day moving average (MA) of 1.28, above the 50-day MA of 1.29, and below the 200-day MA of 2.30, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 53.34 is Neutral, neither overbought nor oversold. The STOCH value of 57.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TOVX.

Theriva Biologics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.36B	3.88	-42.93%	2.87%	17.85%	1.45%
TOVX	45 Neutral	$3.90M	―	-87.31%	―	―	6.87%
JAGX	41 Neutral	$8.75M	―	-522.60%	―	19.75%	95.65%
TTNP	34 Underperform	$3.52M	―	-103.63%	―	-100.00%	28.48%

Theriva Biologics Corporate Events

Theriva Biologics Reports Positive VIRAGE Phase 2b Results

On March 31, 2025, Theriva Biologics announced positive outcomes from a second Independent Data Monitoring Committee (IDMC) review of the VIRAGE Phase 2b clinical trial for VCN-01 in combination with chemotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC). The review found VCN-01 to be well tolerated with an adverse event profile consistent with previous trials, indicating the feasibility of repeated dosing. This development could guide the design of a potential Phase 3 trial, impacting the company’s future clinical strategies and regulatory discussions.